Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that Andreas Johannesson has been appointed interim CFO, effective 5 March 2020.
|
LUND, Sweden, March 5, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that Andreas Johannesson has been appointed interim CFO, effective 5 March 2020. The recruitment process for a permanent CFO is ongoing. As previously announced, Per-Olof Schrewelius will leave the position as CFO at Alligator. Andreas brings to Alligator a wealth of experience from various CFO, interim CFO and other financial positions in international companies like Metso, Haldex, Åhléns, Fitness24Seven and orthopedic business TeamOlmed. Andreas also has a background in strategic consultancy within R&D and Innovation through appointments at McKinsey and Connecta. For further information, please contact: The information was submitted for publication, through the agency of the contact person set out above, at 1:45 p.m. CET on 5 March 2020. About Alligator Bioscience This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE Alligator Bioscience |
||||
Company Codes: Bloomberg:ATORX@SS, ISIN:SE0000767188, RICS:ATORX.ST, Stockholm:ATORX |